Evaluation of serum levels of cathepsin S among colorectal cancer patients

Ann Med Surg (Lond). 2022 May 24:78:103831. doi: 10.1016/j.amsu.2022.103831. eCollection 2022 Jun.

Abstract

Objective: Colorectal cancer is the third most common cancer worldwide. Cathepsins are protease that are known to be involved in cancer progression and metastasis. The aim of this study is to evaluate the levels of serum cathepsin S in patients and control subjects and its effects on the prognosis of the cancer.

Methods: In this case-control study, colorectal cancer patients referred to our gastroenterology clinic were included. The control group consisted of healthy individuals. Cathepsin S levels were analyzed in these patients and the check list consisting of demographic data, cancer stage, colonoscopy findings, CEA marker and cathepsin S levels were recorded.

Results: Of 80 patients and healthy controls included in the study, age, gender and BMI were not significantly different among the two groups, p = 0.265, p = 0.752 and p = 0.2, respectively. Cathepsin S levels were significantly greater in-patient group p < 0.001 and was significantly correlated with the stage of the tumor. CEA marker was also linear related with the increased levels of cathepsin S, p < 0.001.

Conclusion: Our study concluded that cathepsin S is elevated in the cancer patients and can be a significant marker for the prognosis of colorectal cancer.

Keywords: Cathepsin S; Colorectal cancer; Gastroenterology; Marker; Metastasis; Serum levels.